The Nijmegen-Bethesda assay (NBA) 1 is the preferred method for measurement of inhibitors to factor VIII (FVIII 
receiving immune tolerance induction therapy. 6 Other investigators have proposed heating patient plasma to 58°C for 90 minutes, 7 and a recent analysis of PHT at 58°C for 90 minutes using specimens from patients with acquired HA reported an increase in the percentage of positive samples as measured by NBA and anti-FVIII enzyme-linked immunosorbent assay in heated vs unheated samples. These results were complicated by the observation that a subset of specimens that tested positive for FVIII antibodies by ELISA without PHT tested negative upon heating. 4 Pre-analytical heat treatment of inhibitor specimens for 30 minutes at 56°C is an established, validated technique, but data exploring the effects of a range of PHT temperature and duration on inhibitor detection and on the antibodies that impose inhibition are limited.
The goal of this study was to define optimal PHT conditions that limit interference by onboard factor in functional inhibitor assays while maintaining, or increasing, the amount of stable anti-FVIII antibodies in the sample available to impose the inhibitory effects that the assay is designed to measure. With this goal in mind, we examined how heat treatment of plasma over a range of temperatures affects the levels of antifactor VIII IgG 4 detectable by fluorescence immunoassay (FLI).
Several studies have shown anti-FVIII IgG 4 to be the best immunologic indicator of the presence of a functional inhibitor to FVIII. [8] [9] [10] [11] In addition, we examined the stability of rFVIII under the various PHT conditions tested.
| MATERIALS AND METHODS

| Subjects
The specimens used in the study were from a healthy donor and from 
| Nijmegen-Bethesda assay
Factor VIII inhibitors were measured by the CDC-NBA as previously described, 3 including PHT with specimens heated to 56°C for 30 minutes and then centrifuged at 2700 g for 5 minutes at room temperature prior to testing. 
| Fluorescence immunoassay
The anti-FVIII FLI was performed as previously described. 11 Briefly, The threshold for positivity was set at 2 standard deviations above the mean MFI of the results obtained for healthy donors. anti-FVIII IgG 4 FLI was performed as described above.
| Effects of heat treatment on levels of detectable anti-FVIII IgG 4 in plasma
| Statistical methods
Statistical analysis was performed by paired t test using GraphPad Prism (GraphPad Software, San Diego, CA) using a significance level of P = .05.
| RESULTS AND DISCUSSION
The effects of different levels of PHT on free anti-FVIII antibody levels in specimens from one healthy donor and 3 patients with HA are shown in Figure 1 . Heating of plasma samples to 56°C for 30 min- Taken together, the data presented in Figure 1 argue that exposure to 60°C or extending incubations beyond 60 minutes at 56 or 58°C are not optimal conditions for maintaining anti-FVIII IgG 4 levels.
Accordingly, further evaluation of PHT on anti-FVIII IgG 4 levels measured in specimens from 5 additional HA patients with inhibitor titres >0.5 NBU focused on PHT at 56 or 58°C for 30 or 60 minutes. This discrepancy is likely explained by differences in antibody profiles across inhibitor-positive patients, which have been shown to include antibodies of multiple subclasses and affinities. 14 High-affinity antibodies, which bind tightly to their target, are more efficiently blocked in competitive inhibition assays compared to low-affinity antibodies because, once bound, high-affinity antibodies are less likely than lowaffinity antibodies to disengage the inhibitor and bind the assay target. The findings from the current study confirm that PHT decreases the ability of FVIII to react with anti-FVIII antibodies and supports our previous observation that heating to 56°C for 30 minutes decreased both FVIII activity and FVIII antigen to <1 IU/mL. 3 Although the number of patient specimens evaluated in the current study is relatively small, the data derived from the study provide compelling evidence that PHT performed above 56°C may reduce the amount of anti-FVIII IgG 4 in specimens, which will detrimentally affect the accuracy of inhibitor testing.
Taken together, these data demonstrate that 56°C is the optimal temperature for PHT in the NBA for FVIII inhibitors because it minimizes interference by onboard FVIII without decreasing levels of inhibitory antibodies.
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